$95 Billion is the total value of Versant Venture Management, LLC's 7 reported holdings in Q4 2017. The portfolio turnover from Q3 2017 to Q4 2017 was 12.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BOLD | Sell | Audentes Therapeutics, Inc. | $37,644,219,000 | -26.0% | 1,204,615 | -33.3% | 39.61% | +2.3% |
| AKAOQ | Achaogen, Inc. | $13,759,572,000 | -33.2% | 1,281,152 | 0.0% | 14.48% | -7.7% | |
| OCUL | Ocular Therapeutix, Inc. | $9,858,459,000 | -28.8% | 2,215,384 | 0.0% | 10.37% | -1.6% | |
| CBAY | CymaBay Therapeutics, Inc. | $9,647,127,000 | +16.8% | 1,048,601 | 0.0% | 10.15% | +61.4% | |
| IMDZ | ImmuneDesign Corp. | $8,612,019,000 | -62.9% | 2,208,210 | 0.0% | 9.06% | -48.8% | |
| EYES | Second Sight Medical Products, Inc. | $8,581,582,000 | +59.2% | 4,492,975 | 0.0% | 9.03% | +120.0% | |
| CLVS | Clovis Oncology, Inc. | $6,926,140,000 | -17.4% | 101,855 | 0.0% | 7.29% | +14.2% | |
| OPGN | Exit | OpGen, Inc. | $0 | – | -2,554,211 | -100.0% | -0.60% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-01-25
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 35 | Q2 2023 | 10.2% |
| Clovis Oncology, Inc. | 32 | Q3 2022 | 53.2% |
| CRISPR Therapeutics AG | 23 | Q3 2023 | 77.2% |
| Ocular Therapeutix, Inc. | 22 | Q4 2020 | 18.0% |
| Gritstone Oncology, Inc. | 18 | Q3 2023 | 25.4% |
| Achaogen, Inc. | 18 | Q1 2019 | 23.5% |
| Adverum Biotechnologies, Inc. | 15 | Q3 2023 | 21.0% |
| Second Sight Medical Products, Inc. | 15 | Q3 2020 | 9.0% |
| Audentes Therapeutics, Inc. | 13 | Q3 2019 | 39.6% |
| Aligos Therapeutics, Inc. | 12 | Q3 2023 | 15.7% |
View Versant Venture Management, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-08 |
| 13F-HR | 2023-11-03 |
| 13F-HR | 2023-08-09 |
| 13F-HR | 2023-05-11 |
| 144 | 2023-04-20 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-10 |
| 13F-HR | 2022-08-11 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-11 |
View Versant Venture Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.